drugset
Drugs / 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
last change Nov 1994 re-read 3 minutes ago

2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione

also known as NTBC
Developed for
tyrosinemia type I
Investigated by
National Center for Research Resources (NCRR) · University of Michigan

Trials 1

today NCT00004333 · Ph 2
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00004333 Nov 1994 → ? tyrosinemia type I National Center for Research Resources (NCRR) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione “2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)” NCT00004333 ↗
Known as NTBC ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004333 ↗
Action Inhibit “The enzyme inhibitor” NCT00004333 ↗
Route Oral “is administered orally” NCT00004333 ↗